Save this content for laterSave this content on your device for later, even while offline Sign in with FacebookSign in with your Facebook account Close

EU regulator: No more problems with Roche drugs

By: The Associated Press
November 19, 2013 Updated: November 19, 2013 at 7:46 am
0

LONDON (AP) — The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.

Last year, the agency took action against Roche after alleging the Swiss drug maker failed to properly report side effects for the medicines, including the cancer drugs Avastin, Herceptin and Xeloda. British authorities said there were "serious shortcomings" in how Roche AG reported potential problems.

In a statement Tuesday, the European regulator said further safety data on the medicines showed "the balance of benefits and risks of these medicines has not been affected and there is no new advice regarding their use." It said Roche continued to provide additional information as part of their obligatory follow-up.

Comment Policy
Register to the Colorado Springs Gazette
Incognito Mode Your browser is in Incognito mode

You vanished!

We welcome you to read all of our stories by signing into your account. If you don't have a subscription, please subscribe today for daily award winning journalism.

Register to the Colorado Springs Gazette
Register to the Colorado Springs Gazette
Subscribe to the Colorado Springs Gazette

It appears that you value local journalism. Thank you.

Subscribe today for unlimited digital access with 50% fewer ads for a faster browsing experience.

Already a Subscriber? LOGIN HERE

Subscribe to the Colorado Springs Gazette

It appears that you value local journalism. Thank you.

Subscribe today for unlimited digital access with 50% fewer ads for a faster browsing experience.

Subscribe to the Colorado Springs Gazette

Some news is free.
Exceptional journalism takes time, effort and your support.

Already a Subscriber? LOGIN HERE

articles remaining
×
Thank you for your interest in local journalism.
Gain unlimited access, 50% fewer ads and a faster browsing experience.